Epiomic Epidemiology Series: Fabry Disease Forecast in 21 Major Markets 2018–2028

June 2018 | 74 pages | ID: E17D2B7C68CEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Fabry Disease in 21 Major Markets

Fabry disease is a lysosomal storage disorder, caused by a genetic defect in the alpha-galactosidase-A gene (αGLA-gene), localized on the long arm of the X-chromosome (Xq22). This gene is essential in the breakdown of fatty substances, otherwise substances like globotriaosylceramide, will accumulate in the arteries, narrowing them and reducing blood flow around the body. It is a multi-system disorder characterised by dermatologic angiokeratoma corporis diffusum and purpura haemorrhagica nodularis, but also affects ocular, auditory, cardiac, digestive and renal systems.

This report provides the current prevalent population for Fabry Disease across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Austria, Portugal, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Fabry disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Fabry disease include:

• Angiokeratoma
• Cornea verticillata (corneal whorling)
• Hearing loss
• Tinnitus
• Proteinuria
• Cardiac hypertrophy & arrhythmias
• Sweating dysfunction

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

REASON TO BUY

• Able to quantify patient populations in global Fabry disease market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Fabry disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Fabry disease prevalent population.
• Identify sub-populations within Fabry disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Fabry disease patients.

Contents

INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS/FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR FABRY DISEASE
FEATURES OF FABRY DISEASE PATIENTS
  FABRY DISEASE SYMPTOM GROUPS
  COMORBIDITIES OF FABRY DISEASE PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Questions to help diagnosis of Hearing Loss
Table 2. Prevalence of Fabry disease, total (000s)
Table 3. Prevalence of Fabry disease, males (000s)
Table 4. Prevalence of Fabry disease, females (000s)
Table 5. Fabry disease patients with auditory involvement by severity of hearing loss, total (000s)
Table 6. Fabry disease patients with auditory involvement by severity of hearing loss, total (000s)
Table 7. Fabry disease patients with urinary/renal involvement by type of impairment, total (000s)
Table 8. Fabry disease patients with neurological symptoms/pain, total (000s)
Table 9. Fabry disease patients with dermatological symptoms, total (000s)
Table 10. Fabry disease patients with cardiac symptoms, total (000s)
Table 11. Fabry disease patients with cerebrovascular symptoms, total (000s)
Table 12. Fabry disease patients with gastrointestinal symptoms, total (000s)
Table 13. Fabry disease patients with renal/urinary symptoms, total (000s)
Table 14. Fabry disease patients with auditory symptoms, total (000s)
Table 15. Fabry disease patients with ocular symptoms, total (000s)
Table 16. Fabry disease patients with vascular symptoms, total (000s)
Table 17. Fabry disease patients with right ventricular hypertrophy, total (000s)
Table 18. Abbreviations and acronyms used in the report
Table 19. USA prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 20. USA prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 21. Canada prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 22. Canada prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 23. France prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 24. France prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 25. Germany prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 26. Germany prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 27. Italy prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 28. Italy prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 29. Spain prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 30. Spain prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 31. UK prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 32. UK prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 33. Poland prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 34. Poland prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 35. Netherlands prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 36. Netherlands prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 37. Austria prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 38. Austria prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 39. Portugal prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 40. Portugal prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 41. Russia prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 42. Russia prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 43. Turkey prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 44. Turkey prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 45. Japan prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 46. Japan prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 47. China prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 48. China prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 49. South Korea prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 50. South Korea prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 51. India prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 52. India prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 53. Australia prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 54. Australia prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 55. Brazil prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 56. Brazil prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 57. Mexico prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 58. Mexico prevalence of Fabry disease by 5-yr age cohort, females (000s)
Table 59. Argentina prevalence of Fabry disease by 5-yr age cohort, males (000s)
Table 60. Argentina prevalence of Fabry disease by 5-yr age cohort, females (000s)